Revelation Biosciences Inc. to Present at 2021 BIO Digital Conference

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that James Rolke, Revelation’s Chief Executive Officer, will present a corporate overview at the BIO Digital Conference, which is being held June 10-11 and 14-18, 2021.

The presentation will be available to registered conference attendees for on-demand viewing June 10, 2021, at 9:00 a.m. Eastern Time. For more information, please visit the Company Presentations section on the conference website. A replay of the presentation will be available on the Presentations’ section of the company’s website at .

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx‑99, the lead therapeutic candidate, is an intranasal immunomodulator for the prevention or treatment of viral infections including Influenza A, Influenza B, parainfluenza, rhinovirus respiratory syncytial virus and SARS-CoV-2 including its variants. REVTx‑200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx‑501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. For more information on Revelation, please visit


Company Contacts

Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.


Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.


Source: Revelation Biosciences Inc.

Back to news